Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Shire Gets Positive CHMP Opinion for Hemophilia A Drug

Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

    Novartis (NVS) Arm's Biosimilars Study Results Encourage

    Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

      Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

      Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

        Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

        Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

          Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

          Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

            Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

            Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

              Arpita Dutt headshot

              Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

              Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                  Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

                  Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

                    Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

                    Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.

                      Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                      Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                        Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

                        Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

                          Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

                          Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

                            ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up

                            ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.

                              Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                              Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

                                Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

                                Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.

                                  Is a Beat in the Cards for Mylan (MYL) This Earnings Season?

                                  Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.

                                    What's in the Cards for Prothena (PRTA) in Q3 Earnings?

                                    Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

                                      Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?

                                      ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.

                                        What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

                                        Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

                                          What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

                                          Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                                            Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat

                                            Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.

                                              What to Expect From Epizyme (EPZM) This Earnings Season?

                                              Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.

                                                Mark Vickery headshot

                                                Top Research Reports for Lockheed Martin, 3M & T-Mobile

                                                Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), 3M (MMM), and T-Mobile (TMUS).

                                                  Can AbbVie (ABBV) Spring a Surprise this Earnings Season?

                                                  Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.